Lineage Cell Therapeutics LCTX reported its Q3 earnings results on Thursday, November 9, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics reported in-line EPS of $-0.04 versus an estimate of $-0.04.
Revenue was down $1.75 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 2.13% increase in the share price the next day.
Here's a look at Lineage Cell Therapeutics's past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.04 | -0.04 | -0.04 | -0.03 |
| EPS Actual | -0.03 | -0.03 | -0.03 | -0.04 |
| Revenue Estimate | 2.20M | 2.01M | 2.57M | 3.90M |
| Revenue Actual | 3.23M | 2.39M | 1.90M | 3.00M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.